Human TRANCE/TNFSF11/RANK L Antibody Summary
Gln73-Asp317 (Ala194Gly)
Accession # O14788
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Osteoclast-Like Cell Form-ation Induced by TRANCE/ TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody. In the presence of Recombinant Mouse M-CSF (20 ng/mL, 416-ML), Recombinant Human TRANCE/ TNFSF11/RANK L (390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) solution assay. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/TNFSF11/ RANK L (10 ng/mL) is neutral-ized (green line) by increasing concentrations of Goat Anti-Human TRANCE/TNFSF11/ RANK L Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF626). The ND50 is typically 0.01-0.04 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRANCE/TNFSF11/RANK L
RANK Ligand (receptor activator of NF-kappa B ligand [RANKL], also called TNF-related activation-induced cytokines (TRANCE), osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]), is a member of the tumor necrosis factor (TNF) family. RANK Ligand was originally identified as an immediate early gene upregulated by T cell receptor stimulation. The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids. The extracellular domain contains two potential N‑linked glycosylation sites. Mouse and human RANK Ligand share 85% amino acid identity. RANK Ligand is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes. The multi-functions of RANK Ligand include induction of activation of the c-jun N‑terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis, and lymph node organogenesis. RANK is the cell surface signaling receptor of RANK Ligand. RANK has been shown to undergo receptor clustering during signal transduction. Osteoprotegerin, a soluble member of the TNF receptor family which binds RANK Ligand, is a naturally occurring decoy receptor that counterbalances the effects of RANK Ligand.
- Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
- Anderson, D.M. et al. (1997) Nature 390:175.
- Nakagawa, N. et al. (1998) Biochem. Biophys. Res. Commun. 245:382.
- Kong, Y-Y. et al. (1999) Nature 397:315.
Product Datasheets
Citations for Human TRANCE/TNFSF11/RANK L Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases
Authors: Benjamin Navet, Kosei Ando, Jorge William Vargas-Franco, Régis Brion, Jérome Amiaud, Kanji Mori et al.
Cancers (Basel)
-
A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis
Authors: Justin R Savage
PLoS ONE, 2016-06-16;11(6):e0157310.
Applications: Binding Assay -
Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Authors: Buckle, Clive He, De Leenheer, Evy, Lawson, Michelle, Yong, Kwee, Rabin, Neil, Perry, Mark, Vanderkerken, Karen, Croucher, Peter Ia
PLoS ONE, 2012-08-29;7(8):e41127.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
Authors: Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D
Am. J. Pathol., 2003-11-01;163(5):2021-31.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human TRANCE/TNFSF11/RANK L Antibody
There are currently no reviews for this product. Be the first to review Human TRANCE/TNFSF11/RANK L Antibody and earn rewards!
Have you used Human TRANCE/TNFSF11/RANK L Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image